title: Taxane benefit in breast cancer--a role for grade and chromosomal stability.
abstract: Chromosomal instability, which is a characteristic of many human cancers, contributes to intratumour heterogeneity and has been functionally implicated in resistance to taxane therapy in tumour models. However, defining the status of tumour chromosomal instability in a given tumour to test this hypothesis remains challenging. Measurements of numerical and structural chromosomal heterogeneity demonstrate that histological grade correlates with chromosomal instability in oestrogen receptor (ER)-positive breast cancer. Using data on adjuvant taxane therapy in women with breast cancer, we propose that patients with low-grade ER-positive tumours, which are thought to be chromosomally stable, might derive unexpected benefit from taxane therapy. We discuss the implications of the relationships between tumour grade, chromosomal instability and intratumour heterogeneity, the development of high-throughput methods to define tumour chromosomal instability and the potential use of chromosomal instability to tailor therapy.
authors: Cancer Research UK Section of Clinical Trials, The Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton SM2 5NG, UK. roger.ahern@icr.ac.uk
authors: Roger P
authors: RP
authors: A'Hern
authors: Mariam
authors: M
authors: Jamal-Hanjani
authors: A Marcell
authors: AM
authors: Szász
authors: Stephen R D
authors: SR
authors: Johnston
authors: Jorge S
authors: JS
authors: Reis-Filho
authors: Rebecca
authors: R
authors: Roylance
authors: Charles
authors: C
authors: Swanton
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D043171:Chromosomal Instability / Q000187:drug effects*; D005260:Female; D006801:Humans; D060787:Neoplasm Grading; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D043823:Taxoids; C080625:taxane
references: Lancet. 2011 Nov 19;378(9805):1812-23
references: 22098854
references: Nat Rev Clin Oncol. 2011 Mar;8(3):135-41
references: 21364686
references: Curr Drug Targets. 2010 Oct;11(10):1341-50
references: 20840077
references: Clin Cancer Res. 2002 May;8(5):1210-6
references: 12006540
references: Br J Cancer. 1990 May;61(5):671-4
references: 2159768
references: Nature. 2013 Feb 28;494(7438):492-496
references: 23446422
references: Adv Exp Med Biol. 2010;676:137-47
references: 20687474
references: Cell Cycle. 2006 Apr;5(8):818-23
references: 16628000
references: Lancet. 2012 Feb 4;379(9814):390-2
references: 22152852
references: Br J Cancer. 1987 Apr;55(4):449-54
references: 3580268
references: Cancer Cell. 2005 Jul;8(1):7-12
references: 16023594
references: Int J Biol Markers. 2001 Jan-Mar;16(1):56-61
references: 11288957
references: Cancer. 1988 Aug 1;62(3):521-30
references: 3390793
references: Anal Quant Cytol Histol. 1995 Dec;17(6):406-12
references: 8750355
references: Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2964-9
references: 15703300
references: Cancer Cell. 2003 Jan;3(1):51-62
references: 12559175
references: Trends Cell Biol. 1999 Dec;9(12):M57-60
references: 10611684
references: Cancer Res. 2011 May 15;71(10):3447-52
references: 21270108
references: Cancer. 1998 Oct 15;83(8):1529-39
references: 9781946
references: Clin Cancer Res. 2001 Apr;7(4):909-17
references: 11309341
references: Breast Cancer Res. 2009;11(1):R12
references: 19239702
references: Lancet. 2012 Feb 4;379(9814):432-44
references: 22152853
references: Lancet Oncol. 2010 Apr;11(4):358-65
references: 20189874
references: PLoS One. 2013;8(2):e56707
references: 23468873
references: Int J Cancer. 2003 Mar 10;104(1):121-9
references: 12532428
references: Breast Cancer Res. 2010;12(4):207
references: 20804570
references: Nature. 2012 Jun 28;486(7404):537-40
references: 22722843
references: Clin Cancer Res. 2006 Oct 1;12(19):5764-9
references: 17020982
references: Cancer Res. 2004 Feb 1;64(3):904-9
references: 14871819
references: Gut. 2008 Jul;57(7):941-50
references: 18364437
references: N Engl J Med. 2012 Mar 8;366(10):883-892
references: 22397650
references: Breast Cancer Res Treat. 2005 Jul;92(1):77-80
references: 15980994
references: Br J Cancer. 1989 Nov;60(5):693-700
references: 2553094
references: Breast Cancer Res Treat. 2013 Apr;138(2):457-66
references: 23423445
references: J Natl Cancer Inst. 2004 Aug 4;96(15):1141-51
references: 15292386
references: Br J Cancer. 2007 Nov 5;97(9):1218-24
references: 17968427
references: Breast Cancer Res Treat. 2005 Nov;94(1):25-35
references: 16142440
references: Proc Natl Acad Sci U S A. 2009 May 26;106(21):8671-6
references: 19458043
references: Cancer. 2002 Aug 15;95(4):681-95
references: 12209710
references: Diagn Cytopathol. 1994;11(2):151-8
references: 7813363
references: Cell Cycle. 2005 May;4(5):679-82
references: 15846096
references: Cancer Cell. 2007 Jun;11(6):498-512
references: 17560332
references: Int J Cancer. 1999 Aug 20;84(4):381-7
references: 10404090
references: Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14295-300
references: 11121035
references: Cancer. 1988 Jul 15;62(2):331-41
references: 3383134
references: Nat Rev Clin Oncol. 2011 Aug 30;9(1):58-64
references: 21878891
references: Nat Genet. 2005 Jun;37 Suppl:S11-7
references: 15920524
references: J Clin Pathol. 1996 Nov;49(11):931-7
references: 8944615
references: Cancer Res. 2003 Dec 15;63(24):8634-47
references: 14695175
references: EMBO Rep. 2012 Jun 01;13(6):528-38
references: 22595889
references: Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1978-83
references: 11830638
references: Expert Opin Investig Drugs. 2008 Apr;17(4):523-46
references: 18363517
references: Int J Cancer. 2009 Apr 1;124(7):1552-64
references: 19101988
references: Int J Biol Markers. 2000 Oct-Dec;15(4):308-11
references: 11192826
references: Cancer Res. 1998 Feb 1;58(3):396-401
references: 9458079
references: Nature. 1998 Mar 19;392(6673):300-3
references: 9521327
references: Cytometry. 1984 Jul;5(4):420-5
references: 6468180
references: Cytopathology. 2008 Oct;19(5):294-302
references: 18070112
references: Clin Cancer Res. 1996 May;2(5):883-8
references: 9816245
references: J Clin Oncol. 2002 May 1;20(9):2319-26
references: 11981003
references: Cancer Cell. 2010 Jan 19;17(1):77-88
references: 20129249
references: Br J Cancer. 2005 Aug 8;93(3):293-301
references: 16052223
references: Histopathology. 1991 Nov;19(5):403-10
references: 1757079
references: Nat Genet. 2006 Sep;38(9):1043-8
references: 16921376
references: J Clin Oncol. 2009 Jun 10;27(17):2809-15
references: 19380452
references: Br J Cancer. 1957 Sep;11(3):359-77
references: 13499785
references: Trends Genet. 2008 Feb;24(2):64-9
references: 18192061
references: N Engl J Med. 2007 Oct 11;357(15):1496-506
references: 17928597
references: Nat Rev Genet. 2005 Oct;6(10):782-92
references: 16145555
references: Breast J. 2005 Nov-Dec;11(6):448-53
references: 16297090
references: Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2183-94
references: 21784954
references: Cell Cycle. 2009 Oct 15;8(20):3262-6
references: 19806022
references: Diagn Cytopathol. 1997 Oct;17(4):267-71
references: 9316782
references: Ann Oncol. 2005 May;16 Suppl 4:iv14-19
references: 15923415
references: Cancer Res. 2004 Apr 1;64(7):2502-8
references: 15059905
references: Lancet Oncol. 2004 Jun;5(6):372-80
references: 15172358
references: Cell Mol Life Sci. 2012 Jun;69(12):2009-24
references: 22223110